Reported about 24 hours ago
AstraZeneca, valued at $140 billion, has approached Gilead Sciences, worth $96 billion, for a potential merger that could create the world's largest pharmaceutical company by market value. This merger, if successful, would surpass prior significant deals, like the $87.6 billion merger between Bristol-Myers Squibb and Celgene. The merger could be driven by both companies' roles in addressing COVID-19, with Gilead's antiviral Remdesivir and AstraZeneca's vaccine efforts. However, given Gilead's strong financial performance, a merger may be challenging to achieve.
Source: YAHOO